SkyLimit, I would love that to happen. Already NWBO has an entire set of patents, intellectual property, clinical trial data exclusivity, and trade secrets within:
- the DCVax technology platform
- the Flaskworks acquisition
- the in-licensed portfolio from Roswell Park Cancer Center
Likely NWBO already has a "dominant lead" in the dendritic cell IP space for cancer therapy. If they do acquire ImmunoRestoration (DC technology being developed at Moffitt Cancer Center), that dominant lead could easily turn into a dominant position.
Bullish
Market Data 
Markets 
AI
